Hypoglycaemia risk in the first eight weeks of titration with insulin glargine 100 U/mL in previously insulin-naive people with type 2 diabetes mellitus

Brian M Frier, Wolfgang Landgraf, Mei Zhang, Geremia B Bolli, David R Owens

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Patient characteristics associated with hypoglycaemia frequency during insulin glargine 100 U/mL (Gla-100) titration and clinical outcomes at Week 24 were examined using participant-level data from 16 treat-to-target trials of people with type 2 diabetes mellitus inadequately controlled with oral antidiabetes drugs initiating Gla-100 (n=3549). Hypoglycaemia (plasma glucose <3.9 mmol/L or severe) during the first 8 weeks of titration was stratified by number of events (0, 1-3, and ≥4), resulting in 72.5%, 20.6%, and 6.9% of participants in each group, respectively. Glycaemic, body weight, and insulin dose changes from baseline to Weeks 12 and 24 were analysed. Hypoglycaemia was more common in participants with lower BMI and fasting C-peptide, and with sulfonylurea treatment. Glycaemic outcomes at Week 24 were similar in each hypoglycaemia group, despite the Week 24 mean daily dose and dose increase for Gla-100 being highest in participants without hypoglycaemia, and lowest in those experiencing ≥4 events. Hypoglycaemia risk during Gla-100 titration mainly depends on patient characteristics and sulfonylurea use and may delay dose titration, but apparently has little effect on short-term glycaemic control in a clinical trial setting. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Early online date25 Jun 2018
DOIs
Publication statusE-pub ahead of print - 25 Jun 2018

Fingerprint

Dive into the research topics of 'Hypoglycaemia risk in the first eight weeks of titration with insulin glargine 100 U/mL in previously insulin-naive people with type 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this